Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis
Authors' conclusion
The benefit of SGLT-2 inhibitors seems to be additive to background use of CV medications in a broad population of patients. These findings should be interpreted as hypothesis generating because most of the subgroups analysed were not prespecified.
Study context
- Population
- Patients with T2D, heart failure (HF) or CKD in CV outcomes trials (Medline and Embase to September 2022)
- Participants
- 83,804 patients12 trials
- Comparison
- SGLT2 inhibitors by background use vs no use of CV medications
- Outcome
- Composite of:
- CV death
- Hospitalization for HF
Methodological detailssubgroup analysis by background CV medications
- Subgroup analysis by background CV medications
Pooled result
As reported in the abstract
CV death or hospitalization for HF, by background ACEIs/ARBs, angiotensin receptor-neprilysin inhibitors (ARNIs), b-blockers, diuretics, mineralocorticoid receptor antagonists (MRAs) or triple combination therapy
- SGLT2i reduced risk regardless of background CV medication; Hazard ratios (HRs) ranged from
- 0.61 to 0.83
- Subgroup interaction, each subgroup
- P > .1
Further pooled results
CV death, hospitalization for HF, all-cause mortality, MACE or renal events
- No subgroup differences evident for most analyses
Safety
Hyperkalaemia and volume depletion
- No subgroup differences evident for most analyses
Original publication
Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 12 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →